SOUTH SAN FRANCISCO, Calif., Jun 3, 2010 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences, Inc. (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced its participation in the Jefferies 2010 Global Life Sciences Conference to be held June 8 through June 11, 2010 in New York City at the Grand Hyatt New York.
Steven R. Deitcher, M.D., President and Chief Executive Officer, is scheduled to present an overview of the company and its pipeline programs at 1:30 pm Eastern Time on Thursday, June 10, 2010.
A live audio web cast of the presentation will be available for 10 business days on the company's website at www.hanabiosciences.com.
About Hana Biosciences, Inc.
Hana Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing new, differentiated cancer therapies designed to improve and enable current standards of care. The company's lead product candidate, Marqibo(R), potentially treats acute lymphoblastic leukemia and lymphomas. The Company has additional pipeline opportunities some of which, like Marqibo, improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.
The Hana Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3290
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Hana Biosciences, Inc.
CONTACT: Hana Biosciences, Inc. Investor & Media Contacts: Investor Relations Team (650) 588-6641 firstname.lastname@example.org
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
News Provided by COMTEX